Nausieda P A, Weiner W J, Klawans H L
Arch Neurol. 1980 Mar;37(3):132-6. doi: 10.1001/archneur.1980.00500520030003.
One third of a patient population with idiopathic parkinsonism was found to suffer from debilitating, painful dystonic movements of the lower extremities. The prevalence of this involuntary movement disorder was found to be positively correlated with the duration of dopaminergic treatment, but it also occurred occasionally in untreated persons. We suggest that the "dystonic foot response of parkinsonism" is a distinct clinical entity that has no localizing value in frontal lobe disorders and is associated with extrapyramidal disease. This disorder, though exacerbated by dopaminergic therapy, also differs from well-accepted dopaminergic side-effects and does not predictably respond to manipulation of antiparkinsonian medications. Although the precise pathophysiology of this movement disorder is unknown, its response to baclofen therapy suggests that neurotransmitter systems other than cholinergic or dopaminergic ones may be implicated.
在特发性帕金森病患者群体中,有三分之一被发现患有使人虚弱且疼痛的下肢张力障碍性运动。这种非自愿运动障碍的患病率被发现与多巴胺能治疗的持续时间呈正相关,但在未接受治疗的患者中也偶尔会出现。我们认为,“帕金森病的张力障碍性足部反应”是一种独特的临床实体,在额叶疾病中没有定位价值,且与锥体外系疾病相关。这种疾病虽然会因多巴胺能治疗而加重,但也不同于已被广泛认可的多巴胺能副作用,并且对帕金森病药物的调整没有可预测的反应。尽管这种运动障碍的确切病理生理学尚不清楚,但其对巴氯芬治疗的反应表明,可能涉及胆碱能或多巴胺能系统以外的神经递质系统。